A stage 4 pancreatic cancer diagnosis marks metastatic disease, requiring specialized treatment strategies that balance life extension with quality of life. Modern protocols combine chemotherapy, targeted therapy, immunotherapy, and integrated supportive care to manage symptoms and slow progression. Key Takeaways Stage 4 pancreatic cancer treatment is palliative, not curative, focusing on extending survival and maintaining quality of life through systemic therapies and suppor

Stage 4 pancreatic cancer represents advanced disease where cancer has spread beyond the pancreas to distant organs, requiring comprehensive treatment strategies that balance disease control with quality of life. TL;DR FOLFIRINOX and gemcitabine plus nab-paclitaxel remain first-line chemotherapy options for stage 4 pancreatic cancer, with median survival ranging from 6.8 to 11.1 months depending on regimen and patient fitness [1] Dr. Bharat Patodiya provides comprehensive tre

TL;DR Stage 4 pancreatic cancer treatment primarily involves systemic chemotherapy, with FOLFIRINOX achieving median survival of 11 months and gemcitabine/nab-paclitaxel regimens reaching 8.5 months [3] Only 49.1% of stage 4 pancreatic cancer patients receive systemic therapy, with significant disparities based on age, insurance status, and comorbidity scores [4] Targeted therapies including PARP inhibitors for BRCA mutations, NTRK inhibitors, and KRAS inhibitors provide pers

TL;DR FOLFIRINOX chemotherapy extends median overall survival to 11 months in metastatic pancreatic cancer, compared to 8.5 months with gemcitabine plus nab-paclitaxel-based regimens [1] Only 49.1% of stage IV pancreatic cancer patients receive systemic therapy, with significant disparities based on age, insurance status, and treatment facility type [2] Dr.Bh arat Patodiya's multidisciplinary approach integrates medical oncology, surgical consultation, and personalized treat